Familial Hemophagocytic Lymphohistiocytosis (FHLH) is almost universally fatal unless aggressively treated soon after diagnosis, and corrected with allogeneic bone marrow transplantation. All forms of FHLH likely result from genetic defects in the natural down regulating mechanisms of immune/inflammatory responses. Three autosomal recessive gene defects underlie 40-50% of primary (familial) cases worldwide: perforin (20-30%), the major immune cytotoxic protein, MUNC 13- 4 (20%), a protein involved in exocytosis of perforin-bearing cytotoxic granules during apoptosis and STX11, member of soluble N-ethylmaleimide sensitive factor attachment protein receptors (SNARE). Thus in more than half of the FHLH cases, the affected individuals have other as yet unknown genetic alterations. The classic genetic approach to identify these genes, through linkage analysis, has limitations because linkage analysis often leave investigators confronting broad genomic regions containing hundred of genes. Factors such as the impracticality of dramatically increasing the number of families tested, low allelic frequency, and the rarity of families with the disease often prevent the statistical narrowing down of these large regions to identify the involved gene. In this study, we propose a cell-biology-based approach to accelerate the dissection of FHLH susceptibility loci. Our strategy utilizes RNA interference (RNAi), the process where double-stranded RNA induces the homology-dependent degradation of cognate mRNA. The RNAi strategy will be used to identify candidate genes in lymphohistiocytosis susceptibility region on chromosome 9q21.3-22 and among genes coding for SNARE proteins essential for direct, controlled, and very rapid fusion of phospholipids membranes.

Public Health Relevance

Familial Hemophagocytic Lymphohisticytosis, disease genes, identification, microarray, nonsense mediated mRNA decay, RNA interference, SNAREs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI079759-02
Application #
7657422
Study Section
Special Emphasis Panel (ZRG1-IMM-K (52))
Program Officer
Johnson, David R
Project Start
2008-07-15
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2011-06-30
Support Year
2
Fiscal Year
2009
Total Cost
$198,500
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Sumegi, Janos; Nestheide, Shawnagay; Aronow, Bruce et al. (2016) MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. J Allergy Clin Immunol 137:309-312
Sumegi, Janos; Nestheide, Shawnagay V; Barnes, Michael G et al. (2013) Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. Blood 121:e14-24
Al Hawas, Rania; Ren, Qiansheng; Ye, Shaojing et al. (2012) Munc18b/STXBP2 is required for platelet secretion. Blood 120:2493-500
Ye, Shaojing; Karim, Zubair A; Al Hawas, Rania et al. (2012) Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion. Blood 120:2484-92
Sumegi, Janos; Barnes, Michael G; Nestheide, Shawnagay V et al. (2011) Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 117:e151-60